Open AccessPhase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
Author(s) -
Richard Furie,
Ian N. Bruce,
Thomas Dörner,
Manuel Gustavo Leon,
Piotr Leszczyński,
Murray B. Urowitz,
Birgit Haier,
Teri Jimenez,
Clare Brittain,
Jiajun Liu,
Catherine Barbey,
C. Stach
Publication year - 2021
Publication title -
rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.957
H-Index - 173
eISSN - 1462-0332
pISSN - 1462-0324
DOI - 10.1093/rheumatology/keab381
Subject(s) - medicine , placebo , adverse effect , systemic lupus erythematosus , lupus erythematosus , proteinuria , randomized controlled trial , prednisone , clinical trial , immunology , disease , antibody , kidney , alternative medicine , pathology
To evaluate the dose-response, efficacy and safety of dapirolizumab pegol (DZP) in patients with SLE.